BAJAJ BROKING
Dr. Reddy's subsidiary, Aurigene Oncology, has shown positive results in its Phase 1 clinical trial for blood cancer therapy, with 62.5% of patients achieving a complete response. This marks a significant step forward in cancer treatment.
Aurigene Oncology Limited, a subsidiary of Dr. Reddy’s Laboratories, has reported positive results from its first clinical trial of Ribrecabtagene autoleucel (DRL-1801), a new CAR-T cell therapy for multiple myeloma, a type of blood cancer. This breakthrough in cancer treatment marks a significant milestone as it is the first trial of its kind in India to test CAR-T therapy for this condition.
The Phase 1 clinical trial, named the SWASTH study, involved eight patients who had previously undergone multiple treatments for multiple myeloma, with an average of 5.5 prior treatments, including transplants. The trial yielded remarkable results, with all eight patients showing a clinical response to the therapy. Notably, 62.5% of these patients achieved a complete response, demonstrating the potential effectiveness of this new treatment.
Moreover, the therapy exhibited a strong safety profile. None of the patients experienced serious side effects, such as Cytokine Release Syndrome (CRS) or neurotoxicity, which are common concerns in CAR-T cell therapies. These results provide a solid foundation for further research and development.
Following the promising results of the Phase 1 trial, the Drugs Controller General of India (DCGI) has approved the initiation of Phase 2 of the trial, which will involve a larger cohort of patients. This advancement is expected to further evaluate the effectiveness and safety of Ribrecabtagene autoleucel in treating relapsed refractory multiple myeloma patients.
The trial results were recently presented at the 21st annual meeting of the International Myeloma Society in Rio De Janeiro, Brazil, showcasing India’s growing contributions to global cancer research.
With these positive trial outcomes, Aurigene Oncology’s efforts mark a significant advancement in blood cancer treatment. The success of the trial is likely to bolster investor confidence, potentially benefiting Dr. Reddy share price as the company continues its efforts in developing innovative cancer therapies.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Standard Deviation: Meaning, How To Use and Calculate
14 Dec, 2024 | 5 Min. read
Business Forecasting: Definition, Methods, and Models
14 Dec, 2024 | 8 Min. read
Modern Portfolio Theory (MPT): Definition, Types & How To Use
14 Dec, 2024 | 8 Min. read
ASM & GSM Meaning - List of ASM & GSM Stocks
14 Dec, 2024 | 7 Min. read
What Is Nifty BeES? A Guide to Its Benefits and Working
14 Dec, 2024 | 6 Min. read
Nifty Healthcare Index
14 Dec, 2024 | 1 Min. read
Hedging: Meaning, Types, Risks and Strategie
14 Dec, 2024 | 6 Min. read
Bollinger Bands: Meaning, How To Interpret and Use
14 Dec, 2024 | 7 Min. read
Moving Averages Indicator: Variations & Examples
13 Dec, 2024 | 4 Min. read
Learn Everything About Breakout Trading
13 Dec, 2024 | 9 Min. read
Gold Price in India | Gold Drops 1% After Reaching Five-Week High
13 Dec, 2024 | 39 Min. read
Statement of Account and Demat Account: Meaning & Differences
13 Dec, 2024 | 4 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading